EUCTR2020-004887-24-PL进行中（未招募）1 期
Dual Antithrombotic Therapy with Dabigatran and Ticagrelor in Patients with Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI) - ADONIS-PCI
Marcin Gruchala Medical University of Gdansk0 个研究点目标入组 2,230 人开始时间: 2021年1月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male and female patients aged =18 years’
- •2.Patients with new-onset or pre-existing non-valvular AF that have been receiving oral anticoagulant treatment with dabigatran for at least 48 hours or were treatment naïve prior to PCI. AF may be paroxysmal, persistent or permanent, but must not be secondary to a reversible disorder such as MI, pulmonary embolism, recent surgery, pericarditis or thyrotoxicosis unless long-term treatment with an OAC is anticipated.
- •3.Patients presenting with ACS that had undergone a successful PCI with drug-eluting stent (DES) implantation within the previous 72 hours. ACS may be ST-elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), or unstable angina (UA). Successful treatment with PCI is defined as achievement of <30% residual diameter stenosis of the target lesion assessed by visual inspection or quantitative coronary angiography and no in-hospital major adverse cardiac events (AMI or repeat coronary revascularisation of the target lesion). For ACS patients with ST-segment elevation, persistent ST-segment elevation of at least 0.1 mV in at least two contiguous leads or a new left bundle-branch block should be present [27]. For ACS patients without ST-segment elevation, at least two of the following three criteria should be met: (i) ST-segment changes on electrocardiography, indicating ischemia; a positive test of a biomarker, indicating myocardial necrosis; or one of several risk factors (age =60 years; previous myocardial infarction or coronary artery bypass grafting; coronary artery disease with stenosis of =50% in at least two vessels; previous ischemic stroke, transient ischemic attack, carotid stenosis of at least 50%, or cerebral revascularization; diabetes mellitus; peripheral arterial disease; chronic renal dysfunction, defined as a creatinine clearance of <60 ml per minute per 1.73 m2 of body surface area) [40].
- •4.The patient must be able to give informed consent in accordance with ICH GCP guidelines and local legislation and/or regulations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2230
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2230
排除标准
- •1.Mechanical or biological heart valve prosthesis;
- •2.PCI with bare-metal stent insertion;
- •3.Unsuccessful PCI (>30% residual stenosis of the target lesion);
- •4.Cardiogenic shock during current hospitalization;
- •5.Adverse bleeding or ischaemic event during current hospitalization;
- •6.Anaemia (haemoglobin <10 g/dL) or thrombocytopenia (platelet count <100 x109/L) at screening,
- •7.Severe renal impairment (creatinine clearance <30mL/min (estimated CrCl calculated by Cockcroft-Gault equation) at screening;
- •8.Active liver disease at screening, as indicated by at least one of the following:
- •oPersistent alanine aminotransferase (ALT) or aspartate transaminase (AST) >3-fold upper limit of normal (ULN),
- •oKnown active hepatitis C,
- •oKnown active hepatitis B,
- •oKnown active hepatitis A;
- •9.Use of fibrinolytic agents within 24 hours of screening;
- •10.Gastrointestinal bleeding within 1 month prior to screening unless, in the opinion of the Investigator, the cause has been permanently eliminated (e.g., by surgery);
- •11.Major bleeding episode (reduction in the haemoglobin level of at least 2 g/dL, transfusion of at least two units of blood, or symptomatic bleeding in a critical area or organ), including life-threatening bleeding episode (symptomatic intracranial bleeding, bleeding with a decrease in the haemoglobin level of at least 5 g/dL or bleeding requiring transfusion of at least 4 units of blood or inotropic agents or necessitating surgery) within 1 month prior to screening;
- •12.Stroke within 1 month prior to screening;
- •13.Major surgery within 1 month prior to screening;
- •14.Malignancy or radiation therapy within 6 months prior to screening unless, in the opinion of the Investigator, the estimated life expectancy is greater than 36 months;
- •15.History of intraocular, spinal, retroperitoneal, or traumatic intra-articular bleeding unless the causative factor has been permanently eliminated or repaired;
- •16.Haemorrhagic disorder or bleeding diathesis (e.g. von Willebrand disease, haemophilia A or B or other hereditary bleeding disorder, history of spontaneous intra-articular bleeding, history of prolonged bleeding after surgery/intervention);
- •17.Past an organ transplant or patient on the waiting list for organ transplant;
- •18.Need for continued treatment with systemic ketoconazole, itraconazole, posaconazole, cyclosporine, tacrolimus, dronedarone, rifampicin, phenytoin, carbamazepine, St. John’s Wort or any cytotoxic/myelosuppressive therapy.
- •19.Need for continued treatment with non-steroidal anti-inflammatory drugs (NSAIDs);
- •20.Pre-menopausal women (last menstruation =1 year prior to screening) who:
- •oAre pregnant or breastfeeding or
- •oAre not surgically sterile or
- •oAre of childbearing potential and not practicing two acceptable methods of birth control, or do not plan to continue practicing an acceptable method of birth control throughout the trial. Acceptable methods of birth control are oral or parenteral (patch, injection, implant) hormonal contraception, which has been used continuously for at least one month prior to the first dose of study medication, intrauterine device or intrauterine system, double-barrier method of contraception (condom and occlusive cap or condom and spermicidal agent), male sterilization and complete sexual abstinence (if acceptable by local authorities). Periodic abstinence is not an acceptable method of contraception.
- •21.Known allergy to dabigatran, ticagrelor, clopidogrel, aspirin, or to the excipients u
研究者
相似试验
招募中
不适用
RE-DUAL TICLO PCI: Dual Therapy with dabigatran/ticagrelor versus Dual Therapy with dabigatran/clopidogrel in ACS patients with indication for NOAC undergoing PCI.NL-OMON52203Zuyderland Medisch Centrum1,000
招募中
不适用
Efficacy and Safety of Dabigatran for Thromboprophylaxis after Total Knee or Hip Arthroplasty : a pilot studyprimary knee or hip arthroplastyTKA,THA,Dabigatran,DVT,PETCTR20150504001Golden Jubilee Medical Center32
招募中
不适用
Efficacy and Safety of Dabigatran for Thromboprophylaxis after Total Knee Arthroplastypatients underwent knee replacement surgerydabigatran,deep vein thrombosis,pulmonary embolism,new oral anticoagulant,prophylaxis,knee replacement,AsianTCTR20160208001Golden Jubilee Medical Center, Mahidol University32
进行中（未招募）
不适用
Twice-daily oral direct thrombin inhibitor dabigatran in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. - Re-Sonatelong-term prevention of recurrent symptomatic venous thromboembolism (VTE) in patients with symptomatic deep-vein thrombosis (DVT) or pulmonary embolism (PE) who completed 6 to 18 months of treatment with a vitamin K antagonist (VKA).MedDRA version: 9.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisEUCTR2007-002586-12-EEBoehringer Ingelheim RCV GmbH & Co KG1,800
进行中（未招募）
不适用
Twice-daily oral direct thrombin inhibitor dabigatran in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. - Re-SonateEUCTR2007-002586-12-PLBoehringer Ingelheim Pharma GesmbH1,800